The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film.

The present invention provides a three-dimensional bioprinter for fabricating cellular constructs such as tissues and organs using electromagnetic radiation (EMR) at or above 405 nm. The bioprinter includes a material deposition device comprising a cartridge for receiving and holding a composition which contains biomaterial that cures after exposure to EMR. The bioprinter also includes an EMR module that emits EMR at a wavelength of about 405 nm or higher. Also provided is a bioprinter cartridge which contains cells and a material curable at a wavelength of about 405 nm or greater. The cells are present in a chamber and arc extruded through an orifice to form the cellular construct.

The present invention includes compositions and methods of making films, adhesive patches, or composites comprising a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (PCL-PVAc-PEG) and a partially hydrophilic oil, wherein the composition transitions from a viscous liquid, to an adhesive, and to a film as a weight percent (wt %) ratio of PCL-PVAc-PEG to partially hydrophilic oil changes.

The present invention relates to a solid oral extended release pharmaceutical dosage form comprising a cured extended release matrix formulation, the extended release matrix formulation comprising: a therapeutically effective amount of morphine sulfate, and polyethylene oxide.
The invention further relates to a process of preparing the dosage form as well as to a method of treating pain by administering the dosage form

The present disclosure provides a photopolymerizable composition. The photopolymerizable composition includes at least one polypropylene oxide component and an initiator, plus optionally a urethane component, a multifunctional reactive diluent, and/or an inhibitor. The present disclosure also provides an article including the reaction product of the photopolymerizable composition. Typically, the article exhibits an elongation at break of 30% or greater. Further, the present disclosure provides a method of making an article. The method includes (i) providing a photopolymerizable composition and (ii) selectively curing the photopolymerizable composition to form an article. The method optionally also includes (iii) curing unpolymerized polypropylene oxide component, urethane component and/or multifunctional reactive diluent remaining after step (ii). Further, methods are provided, including receiving, by a manufacturing device having one or more processors, a digital object comprising data specifying an article; and generating, with the manufacturing device by an additive manufacturing process, the article based on the digital object. A system is also provided, including a display that displays a 3D model of an article; and one or more processors that, in response to the 3D model selected by a user, cause a 3D printer to create a physical object of an article.

The combination of 3D printing technology plus the additional dimension of transformation over time of the printed object is referred to herein as 4D printing technology. Particular arrangements of the additive manufacturing material(s) used in the 3D printing process can create a printed 3D object that transforms over time from a first, printed shape to a second, predetermined shape.

The present disclosure relates to an oral, extended release pill containing a drug which is homogenously spread throughout a matrix. The pill can be prepared using a hot melt extrusion process and a forming unit. The formed pill meets regulatory guidelines for extended release formulations and can be abuse deterrent to parenteral administration due at least to particle size, viscosity, or purity limitations.

A multilayered polymer composite film includes a water-soluble polymer matrix and a plurality of fibers embedded within the water soluble polymer matrix. The fibers include a water insoluble polymer material and at least one of a non-polymeric hydrophobic therapeutic agent or a non-polymeric hydrophobic cosmetic agent incorporated in the water insoluble polymer material. The fibers have a rectangular cross-section, and extend the entire length of the multilayered polymer composite film.

Describes are support elements for a sole of a shoe, in particular a sports shoe, a sole and a shoe with such a support element, as well as a method for the manufacture of a support element. As examples, the support element includes a first partial member formed of a first material, and a second partial member formed of a second material. The first partial member is mechanically joined to the second partial member in a connection region, wherein the connection region is configured to allow the first partial member to rotate or slide relative to the second partial member. The first partial member, the second partial member, and the connection region can be co-molded and joined together in a single fabricating step.

The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film.